董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Slattery | 男 | Independent Lead Director | 60 | 21.05万美元 | 14.68 | 2025-08-11 |
| Mudit K. Jain | 男 | Independent Director | 57 | 17.05万美元 | 101.47 | 2025-08-11 |
| Kirk Nielsen | 男 | Lead Independent Director | 52 | 16.90万美元 | 178.92 | 2025-08-11 |
| Kevin Hykes | -- | Director, President and Chief Executive Officer | -- | 390.58万美元 | 17.43 | 2025-08-11 |
| Martha Shadan | -- | Independent Director | -- | 15.84万美元 | 10.11 | 2025-08-11 |
| Mitchell C. Hill | -- | Independent Director | -- | 16.80万美元 | 未持股 | 2025-08-11 |
| Kevin J. Ballinger | -- | Independent Director | -- | 15.66万美元 | 未持股 | 2025-08-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brent Binkowski | 男 | Chief Operating Officer | 56 | 未披露 | 未持股 | 2025-08-11 |
| Jared Oasheim | 男 | Chief Financial Officer and Principal Accounting Officer | 43 | 156.89万美元 | 28.05 | 2025-08-11 |
| Paul Verrastro | 男 | Chief Marketing Officer and Chief Strategy Officer | 63 | 未披露 | 未持股 | 2025-08-11 |
| Kevin Hykes | -- | Director, President and Chief Executive Officer | -- | 390.58万美元 | 17.43 | 2025-08-11 |
| Robert Allen John | -- | Chief Revenue Officer | -- | 未披露 | 未持股 | 2025-08-11 |
| Philip B. Adan | -- | Chief Medical Officer | -- | 136.11万美元 | 未持股 | 2025-08-11 |
| Robert John | 男 | Chief Revenue Officer | 53 | 176.24万美元 | 未持股 | 2025-08-11 |
董事简历
中英对照 | 中文 | 英文- Joseph Slattery
-
Joseph Slattery，一直是Replimune Group, Inc.的成员。自2017年起担任董事会成员。此前，他于2019年3月至2020年3月31日担任Replimune Group, Inc.的首席独立董事。2013年10月至2019年12月，他担任Asensus Surgical, Inc.的执行副总裁兼首席财务官。从2010年到2013年，他担任Baxano Surgical, Inc.的执行副总裁兼首席财务官。此前，从1996年到2007年，他在Digene Corporation担任各种职务，包括从2006年到2007年担任首席财务官和财务和信息系统高级副总裁。他是Morphic Therapeutic, Inc.和CVRx Inc.的董事会成员，他曾担任Omega Alpha SPAC, Baxano Surgical, Inc.， Exosome Diagnostics, Inc.和Micromet, Inc.的董事。他持有Bentley University的会计学士学位，是一名注册会计师。
Joseph Slattery has been a member of Replimune Group, Inc.'s Board since 2017. He previously served as Replimune Group, Inc.'s lead independent director from March 2019 until March 31, 2020. Mr. Slattery served as Executive Vice President and Chief Financial Officer of Asensus Surgical, Inc. from October 2013 through December 2019. From 2010 to 2013, Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical, Inc. Previously, from 1996 to 2007, Mr. Slattery served in various roles of increasing responsibility at Digene Corporation, including as Chief Financial Officer and Senior Vice President of Finance and Information Systems from 2006 to 2007. Mr. Slattery currently serves on the board of directors of CVRx Inc. since October 2008 and ImageneBio, Inc. since October 2025. Previously, he served as a director of Morphic Therapeutic, Inc., Omega Alpha SPAC, Baxano Surgical, Inc., Exosome Diagnostics, Inc. and Micromet, Inc. Mr. Slattery received a B.S. in Accounting from Bentley University and is a certified public accountant. - Joseph Slattery，一直是Replimune Group, Inc.的成员。自2017年起担任董事会成员。此前，他于2019年3月至2020年3月31日担任Replimune Group, Inc.的首席独立董事。2013年10月至2019年12月，他担任Asensus Surgical, Inc.的执行副总裁兼首席财务官。从2010年到2013年，他担任Baxano Surgical, Inc.的执行副总裁兼首席财务官。此前，从1996年到2007年，他在Digene Corporation担任各种职务，包括从2006年到2007年担任首席财务官和财务和信息系统高级副总裁。他是Morphic Therapeutic, Inc.和CVRx Inc.的董事会成员，他曾担任Omega Alpha SPAC, Baxano Surgical, Inc.， Exosome Diagnostics, Inc.和Micromet, Inc.的董事。他持有Bentley University的会计学士学位，是一名注册会计师。
- Joseph Slattery has been a member of Replimune Group, Inc.'s Board since 2017. He previously served as Replimune Group, Inc.'s lead independent director from March 2019 until March 31, 2020. Mr. Slattery served as Executive Vice President and Chief Financial Officer of Asensus Surgical, Inc. from October 2013 through December 2019. From 2010 to 2013, Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical, Inc. Previously, from 1996 to 2007, Mr. Slattery served in various roles of increasing responsibility at Digene Corporation, including as Chief Financial Officer and Senior Vice President of Finance and Information Systems from 2006 to 2007. Mr. Slattery currently serves on the board of directors of CVRx Inc. since October 2008 and ImageneBio, Inc. since October 2025. Previously, he served as a director of Morphic Therapeutic, Inc., Omega Alpha SPAC, Baxano Surgical, Inc., Exosome Diagnostics, Inc. and Micromet, Inc. Mr. Slattery received a B.S. in Accounting from Bentley University and is a certified public accountant.
- Mudit K. Jain
-
MuditK.Jain自2009年5月以来一直担任我们的董事会成员。Jain先生目前担任Synergy Venture Partners，LLC的董事总经理，这是一家风险投资公司，他自2013年以来一直担任该职位。Jain先生拥有Visvesvaraya Regional College of Engineering的工商管理硕士学位，宾夕法尼亚大学沃顿商学院的工商管理硕士学位和杜克大学生物医学工程博士学位。
Mudit K. Jain has served as one of directors since July 2020. He has been a Founding General Partner of Treo Ventures I, L.P. formerly known as Strategic Healthcare Investment Partners ("Treo"), a venture capital firm, since September 2018 and previously served as a Managing Director at Synergy Venture Partners, LLC, a venture capital investment firm, from April 2007 to September 2018. Dr. Jain also has served as the CEO and co-founder of NuXcel, a medical device accelerator, since 2018. Dr. Jain currently serves on the boards of directors of Neochord, Inc., Noctrix, Inc., NuXcel and ShiraTronics, Inc., and he was previously a member of the board of directors of Inspire Medical Systems, Inc. Dr. Jain graduated with a B.E. in Electrical Engineering from National Institute of Technology, Nagpur, India. He received his Ph.D. in Biomedical Engineering from Duke University and his M.B.A. from The Wharton School of the University of Pennsylvania. - MuditK.Jain自2009年5月以来一直担任我们的董事会成员。Jain先生目前担任Synergy Venture Partners，LLC的董事总经理，这是一家风险投资公司，他自2013年以来一直担任该职位。Jain先生拥有Visvesvaraya Regional College of Engineering的工商管理硕士学位，宾夕法尼亚大学沃顿商学院的工商管理硕士学位和杜克大学生物医学工程博士学位。
- Mudit K. Jain has served as one of directors since July 2020. He has been a Founding General Partner of Treo Ventures I, L.P. formerly known as Strategic Healthcare Investment Partners ("Treo"), a venture capital firm, since September 2018 and previously served as a Managing Director at Synergy Venture Partners, LLC, a venture capital investment firm, from April 2007 to September 2018. Dr. Jain also has served as the CEO and co-founder of NuXcel, a medical device accelerator, since 2018. Dr. Jain currently serves on the boards of directors of Neochord, Inc., Noctrix, Inc., NuXcel and ShiraTronics, Inc., and he was previously a member of the board of directors of Inspire Medical Systems, Inc. Dr. Jain graduated with a B.E. in Electrical Engineering from National Institute of Technology, Nagpur, India. He received his Ph.D. in Biomedical Engineering from Duke University and his M.B.A. from The Wharton School of the University of Pennsylvania.
- Kirk Nielsen
-
Kirk Nielsen自2011年9月以来一直担任我们的董事会成员。尼尔森先生自2019年1月起担任专注于医疗技术的投资公司Vensana Capital的管理合伙人，自2011年1月起担任专注于梦百合的风险投资公司Versant Ventures的董事总经理。他目前担任几家私人公司的董事会成员，包括:Metavention公司、Monteris Medical公司、Respicardia公司、Veran Medical Technologies公司。Mr.Nielsen在Harvard College获得A.B.，在Harvard Business School获得M.B.A.。
Kirk Nielsen has served as a member of board of directors since July 2025 and previoly served as a member of board of directors from December 2020 to July 2023. Mr. Nielsen has served as a managing partner at Vensana Capital, a medtech foced investment firm, since January 2019 and as a managing director at Versant Ventures, a healthcare foced venture capital firm, since January 2011. Mr. Nielsen currently serves on the board of directors of CVRx and several boards of directors for private companies, including Elucent Medical, iVEAcare, Moxe Health, Okami Medical, Rampart, and Vensana Innovation, and he previoly served on the boards of directors for numero other companies, including Alleviant Medical, Artelon, and Inari Medical. Mr. Nielsen holds an A.B. from Harvard College and an M.B.A. from Harvard Biness School. - Kirk Nielsen自2011年9月以来一直担任我们的董事会成员。尼尔森先生自2019年1月起担任专注于医疗技术的投资公司Vensana Capital的管理合伙人，自2011年1月起担任专注于梦百合的风险投资公司Versant Ventures的董事总经理。他目前担任几家私人公司的董事会成员，包括:Metavention公司、Monteris Medical公司、Respicardia公司、Veran Medical Technologies公司。Mr.Nielsen在Harvard College获得A.B.，在Harvard Business School获得M.B.A.。
- Kirk Nielsen has served as a member of board of directors since July 2025 and previoly served as a member of board of directors from December 2020 to July 2023. Mr. Nielsen has served as a managing partner at Vensana Capital, a medtech foced investment firm, since January 2019 and as a managing director at Versant Ventures, a healthcare foced venture capital firm, since January 2011. Mr. Nielsen currently serves on the board of directors of CVRx and several boards of directors for private companies, including Elucent Medical, iVEAcare, Moxe Health, Okami Medical, Rampart, and Vensana Innovation, and he previoly served on the boards of directors for numero other companies, including Alleviant Medical, Artelon, and Inari Medical. Mr. Nielsen holds an A.B. from Harvard College and an M.B.A. from Harvard Biness School.
- Kevin Hykes
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Martha Shadan
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mitchell C. Hill
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kevin J. Ballinger
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Brent Binkowski
Brent Binkowski，他一直是高级运营副总裁（2015年6月以来）。加入之前，他曾担任CeloNova BioSciences公司（一个医疗设备公司，专注于栓塞和血管设备）的运营副总裁（2013年2月至2015年6月）。他曾任职American Medical Systems公司（医疗设备公司，专注于泌尿外科市场）（2003年以来），担任高级运营董事（2011年1月至2013年2月）、价值流董事（从2008年2月到2011年1月）。
Brent Binkowski has served as Senior Vice President of Operations since June 2015. Prior to joining, Mr. Binkowski served as Vice President of Operations for CeloNova BioSciences, Inc., a medical device company focused on embolization and vascular devices, from February 2013 to June 2015. Mr. Binkowski was employed by American Medical Systems, a medical device company focused principally on the urology market, since 2003 serving as Senior Director of Operations from January 2011 to February 2013 and Value Stream Director from February 2008 to January 2011.- Brent Binkowski，他一直是高级运营副总裁（2015年6月以来）。加入之前，他曾担任CeloNova BioSciences公司（一个医疗设备公司，专注于栓塞和血管设备）的运营副总裁（2013年2月至2015年6月）。他曾任职American Medical Systems公司（医疗设备公司，专注于泌尿外科市场）（2003年以来），担任高级运营董事（2011年1月至2013年2月）、价值流董事（从2008年2月到2011年1月）。
- Brent Binkowski has served as Senior Vice President of Operations since June 2015. Prior to joining, Mr. Binkowski served as Vice President of Operations for CeloNova BioSciences, Inc., a medical device company focused on embolization and vascular devices, from February 2013 to June 2015. Mr. Binkowski was employed by American Medical Systems, a medical device company focused principally on the urology market, since 2003 serving as Senior Director of Operations from January 2011 to February 2013 and Value Stream Director from February 2008 to January 2011.
- Jared Oasheim
Jared Oasheim自2020年10月起担任首席财务官，拥有超过15年的财务经验。Oasheim先生于2015年8月加入CVRx，担任财务副总裁/财务总监。在加入CVRx之前，在毕马威会计师事务所（KPMG LLP）开始其职业生涯后，他曾在三家新兴成长型技术公司担任过各种领导职务。Oasheim先生毕业于明尼苏达大学卡尔森管理学院，获得会计学学士学位，是一名非在职注册会计师。
Jared Oasheim has been Chief Financial Officer since October 2020 and has over 15 years of finance experience. Mr. Oasheim joined CVRx in August 2015 as VP of Finance/Controller. Prior to CVRx, he held various leadership roles at three emerging growth technology companies after starting his career with KPMG LLP. Mr. Oasheim graduated from the Carlson School of Management at the University of Minnesota with a B.S. in Accounting and is a certified public accountant inactive.- Jared Oasheim自2020年10月起担任首席财务官，拥有超过15年的财务经验。Oasheim先生于2015年8月加入CVRx，担任财务副总裁/财务总监。在加入CVRx之前，在毕马威会计师事务所（KPMG LLP）开始其职业生涯后，他曾在三家新兴成长型技术公司担任过各种领导职务。Oasheim先生毕业于明尼苏达大学卡尔森管理学院，获得会计学学士学位，是一名非在职注册会计师。
- Jared Oasheim has been Chief Financial Officer since October 2020 and has over 15 years of finance experience. Mr. Oasheim joined CVRx in August 2015 as VP of Finance/Controller. Prior to CVRx, he held various leadership roles at three emerging growth technology companies after starting his career with KPMG LLP. Mr. Oasheim graduated from the Carlson School of Management at the University of Minnesota with a B.S. in Accounting and is a certified public accountant inactive.
- Paul Verrastro
Paul Verrastro自2021年1月起担任我们的首席营销官，在心律市场拥有30多年的经验。加入CVRX之前，他管理自己的咨询业务，与St.Jude Medical，Abbott Cardiovascular和Medtronic CRDM等客户合作。他的职业生涯始于担任Medtronic的销售代表，在该领域工作十年后，他加入Guidant Corporation，担任植入式心脏去纤颤器营销总监。他随后担任Guidant Corporation（位于欧洲）的所有营销副总裁，后来担任其客户关系管理部门的全球营销副总裁。2011年5月，他重新加入Medtronic，担任全球战略营销副总裁。在他的职业生涯中，他帮助将许多新技术推向市场，包括植入式心脏去纤颤器，心脏再同步疗法，植入式环路记录器和无铅起搏。他拥有雪城大学的学士学位。
Paul Verrastro has been Chief Marketing Officer since January 2021 and has over 30 years of experience in the cardiac rhythm market. Prior to joining CVRx, he managed his own consulting business, working with clients such as St. Jude Medical, Abbott Cardiovascular and Medtronic CRDM. He started his career as a sales representative for Medtronic, and after ten years in the field, he joined Guidant Corporation as Director of Implantable Cardiac Defibrillators Marketing. He then served as Vice President of Marketing for all of Guidant Corporation in Europe and later as Vice President of Global Marketing for their customer relationship management division. In May of 2011 he rejoined Medtronic as Vice President of Global Strategic Marketing. He holds a B.S. degree from Syracuse University.- Paul Verrastro自2021年1月起担任我们的首席营销官，在心律市场拥有30多年的经验。加入CVRX之前，他管理自己的咨询业务，与St.Jude Medical，Abbott Cardiovascular和Medtronic CRDM等客户合作。他的职业生涯始于担任Medtronic的销售代表，在该领域工作十年后，他加入Guidant Corporation，担任植入式心脏去纤颤器营销总监。他随后担任Guidant Corporation（位于欧洲）的所有营销副总裁，后来担任其客户关系管理部门的全球营销副总裁。2011年5月，他重新加入Medtronic，担任全球战略营销副总裁。在他的职业生涯中，他帮助将许多新技术推向市场，包括植入式心脏去纤颤器，心脏再同步疗法，植入式环路记录器和无铅起搏。他拥有雪城大学的学士学位。
- Paul Verrastro has been Chief Marketing Officer since January 2021 and has over 30 years of experience in the cardiac rhythm market. Prior to joining CVRx, he managed his own consulting business, working with clients such as St. Jude Medical, Abbott Cardiovascular and Medtronic CRDM. He started his career as a sales representative for Medtronic, and after ten years in the field, he joined Guidant Corporation as Director of Implantable Cardiac Defibrillators Marketing. He then served as Vice President of Marketing for all of Guidant Corporation in Europe and later as Vice President of Global Marketing for their customer relationship management division. In May of 2011 he rejoined Medtronic as Vice President of Global Strategic Marketing. He holds a B.S. degree from Syracuse University.
- Kevin Hykes
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Robert Allen John
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Philip B. Adan
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Robert John
Robert John自2024年6月起担任公司首席营收官。他在心律管理、电生理学和心力衰竭领域的临床和销售角色方面拥有超过28年的经验。John先生此前曾于2017年6月至2023年6月在雅培担任心力衰竭和CRM（EMEA）业务部门副总裁，在此之前，他曾于2008年7月至2017年6月担任心力衰竭高级副总裁。John先生的职业生涯始于辉瑞、Guidant和美敦力，担任的销售代表和领导职位责任越来越大。John先生获得了北德克萨斯大学的学士学位和阿拉巴马大学的硕士学位。
Robert John has served as the Company's Chief Revenue Officer since June 2024. He has over 28 years of experience in clinical and sales roles in areas of cardiac rhythm management, electrophysiology and heart failure. Mr. John previously served as Divisional Vice President at Abbott for Abbott's Heart Failure and CRM (EMEA) businesses from June 2017 to June 2023, prior to which he served as Senior Vice President, Heart Failure from July 2008 to June 2017. Mr. John's career began with Pfizer, Guidant and Medtronic as a sales representative and leadership positions of increasing responsibility. Mr. John received a B.S. from the University of North Texas and his M.A. from the University of Alabama.- Robert John自2024年6月起担任公司首席营收官。他在心律管理、电生理学和心力衰竭领域的临床和销售角色方面拥有超过28年的经验。John先生此前曾于2017年6月至2023年6月在雅培担任心力衰竭和CRM（EMEA）业务部门副总裁，在此之前，他曾于2008年7月至2017年6月担任心力衰竭高级副总裁。John先生的职业生涯始于辉瑞、Guidant和美敦力，担任的销售代表和领导职位责任越来越大。John先生获得了北德克萨斯大学的学士学位和阿拉巴马大学的硕士学位。
- Robert John has served as the Company's Chief Revenue Officer since June 2024. He has over 28 years of experience in clinical and sales roles in areas of cardiac rhythm management, electrophysiology and heart failure. Mr. John previously served as Divisional Vice President at Abbott for Abbott's Heart Failure and CRM (EMEA) businesses from June 2017 to June 2023, prior to which he served as Senior Vice President, Heart Failure from July 2008 to June 2017. Mr. John's career began with Pfizer, Guidant and Medtronic as a sales representative and leadership positions of increasing responsibility. Mr. John received a B.S. from the University of North Texas and his M.A. from the University of Alabama.